Replies to post #142692 on Biotech Values

[mcbio]

So, best responding group is in the following order: TN/HG, HG but not TN, TN but not HG. To me, the result is still trending toward HG regardless of TN status.

Do you think the data is compelling enough to land CLDX a partner for 011 before the start of Phase 3?

[iwfal]

CLDX -

To me, the result is still trending toward HG regardless of TN status

In the HG without TN status the ORR comparison is 28% vs 20% with a p value near 1.0. I'd suggest it is a stretch to call that a trend. And the PFS data, being both more perceptive and of more clinical and regulatory importance, is HR is about 0.85 with a p value near 1.0. Again, hard to claim even a trend for HG without TN status. So unless they have some amazing OS data in that subgroup I would hope that they kill it.